Circio Holding NOK 50m Capital Raise | Q4 2025

About Circio 

Circio Holding ASA is a biotechnology company developing novel circular RNA expression technology for gene and cell therapy. 

Circio has established a unique circular RNA (circRNA) vector expression technology for next generation RNA, DNA and viral therapeutics. The proprietary circVec platform is based on a modular genetic construct designed for efficient biogenesis of multifunctional circRNA inside target cells. The circVec platform has applications in multiple therapeutic settings, including genetic medicine, cell therapy and chronic disease. It has demonstrated 75-fold increased RNA half-life and up to 40-fold enhanced protein expression vs. conventional mRNA-based viral and non-viral vector systems, with the potential to become a new gold-standard gene expression technology. The circVec R&D activities are being conducted by the wholly owned subsidiary Circio AB in Stockholm, Sweden. 

In parallel, Circio is continuing to develop its legacy immuno-oncology program, TG01, through cost-efficient external academic and industry collaborations. TG01 targets RAS-mutated cancers and is being tested in two clinical trials in Norway and the USA. TG01 is a therapeutic peptide vaccine adjuvanted by STIMULON QS-21 licensed from Agenus Inc. 

About the transaction 

On 8 December 2025 Circio proposed a partially underwritten and presubscribed (88.4%) rights issue of up to NOK 50 million priced at NOK 1.0 per share (the "Rights Issue"). 

The Rights Issue has strong support from several of Circio´s main shareholders and presubscription commitments of NOK 24.2 million in total (48.4%). The Rights Issue will provide Circio with the necessary capital to fund its operations for around twelve months and thereby deliver several important pre-clinical development milestones for its circVec circular RNA expression platform, including the recently announced feasibility study with a major global pharma company. 

Link to press release 

Website: https://www.circio.com/en/